



## Indivior Prepays \$150 Million of Outstanding Debt

Released : 10/09/2018 07:00

RNS Number : 1849A  
Indivior PLC  
10 September 2018

### **Indivior Prepays \$150 Million of Outstanding Debt**

Slough, UK and Richmond, VA, September 10, 2018 - Indivior PLC (LON: INDV) today announced that it has completed the prepayment of \$150 million of its outstanding Term loan facilities. As a result, outstanding borrowing under the Term loan facilities is \$333 million.

#### **For Further Information**

<b>Investor Enquiries</b>	Jason Thompson	VP Investor Relations, Indivior PLC	+1 804 379 1033 jason.thompson@indivior.com
---------------------------	----------------	--	--

#### **About Indivior**

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit [www.indivior.com](http://www.indivior.com) to learn more.

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

UPDUBSVRWSAKRAR